Population Pharmacokinetics of Antibiotics in Critically Ill Children (POPSICLE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-24

Study Completion Date

2020-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infections are common on the Intensive Care for both adult and pediatric patients. Adequately dosing antibiotic treatment is of vital importance but both under- and overdosing is frequent due to pathophysiological changes during critical illness. Moreover, the interplay of age and critical illness is even more understudied.

To optimize antibiotic dosing and outcome of infectious disease, personalized dosing guidelines in critically ill patients are highly needed. In this prospective observational population pharmacokinetic study we will evaluate if target attainment for antibiotics is reached in critically ill children with current dosing guidelines. Using these data, individualized dosing guidelines will be developed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients

NCT02993575

Bacterial Infections

COMPLETED

Antibiotic Dosing in Pediatric Intensive Care

NCT02456974

Pharmacokinetics Amoxicillin-clavulanate Piperacillin-tazobactam +5 more

RECRUITING

Beta-lactam Pharmacokinetics in Secondary Care

NCT03033394

Pharmacokinetics Beta Lactam Adverse Reaction Penicillin Allergy

COMPLETED

Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.

NCT04470973

Sepsis Septic Shock Infection, Bacterial +1 more

UNKNOWN

Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care

NCT05354635

Intensive Care Units, Pediatric

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately one third of all critically ill children develop infectious disease related complications. Mortality due to infections can be as high as 30-45%. In up to 41% of adult critically ill patients antimicrobial dosing recommendations are inadequate, as acute kidney injury, augmented renal clearance, inflammatory response and hypoalbuminaemia all contribute to variation in drug concentrations. This is an important reason for antibiotic treatment failure and emergence of resistance.

Data from adults cannot be directly extrapolated to children, due to developmental changes in the processes involved in drug disposition. Moreover, the interplay of age and critical illness is even more understudied. Hence, to optimize antibiotic dosing and outcome of infectious disease, personalized dosing guidelines in critically ill patients are highly needed.

In this prospective observational population pharmacokinetic study we will evaluate if target attainment for antibiotics is reached in critically ill children with current dosing guidelines. Using these data, individualized dosing guidelines will be developed.

Objectives:

To determine the population pharmacokinetics of antibiotics in critically ill pediatric patients to develop individualized dosing guidelines for antibiotics for this population.

Study design:

Observational study with minimal invasive procedures: population pharmacokinetic study.

Study population:

Critically ill children, admitted on the pediatric intensive care unit (PICU), receiving antibiotics.

Study parameters/endpoints:

Primary:

* To estimate population pharmacokinetic parameters for antibiotics

Secondary:

* To determine the target attainment rate of antibiotic exposure
* To design individualized dosing guidelines for antibiotics

Exploratory:

* To describe variability in kidney function
* To explore the relationship of genetic variation with disposition of pharmacokinetics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Infectious Disease Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Pharmacokinetics

Intervention Type DRUG

* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment
* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)
* Whole blood is stored for DNA analysis
* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacokinetics

* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment
* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)
* Whole blood is stored for DNA analysis
* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Antibiotics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 0 to 18 years of postnatal age;
* \>37 weeks of gestational age (in children less than 6 months of postnatal age);
* Admitted to pediatric intensive care unit;
* Indwelling central line or arterial line in place for clinical purposes, or regular blood work for clinical reasons;
* Antibiotic therapy already prescribed by treating physician;
* Written informed consent (IC).